Asset Acquisition (Details)		9 Months Ended
	Apr. 01, 2024 USD ($) Program director $ / shares shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Assets
Cash and cash equivalents		$ 5,410,000	$ 20,821,000	$ 25,244,000	$ 38,757,000
Total assets		8,936,000	22,683,000
Liabilities assumed:
Accrued expenses and other current liabilities		2,650,000	3,375,000
Total liabilities		$ 10,969,000	$ 12,011,000
Number of shares issued | shares		10,359
Acquired in-process research and development		$ 117,464,000
Common stock, shares authorized | shares	125,000,000	250,000,000
Common Stock
Liabilities assumed:
Number of shares issued | shares		141,982
Trawsfynydd IPR&D
Consideration transferred:
Assumed options	$ 7,085,000
Company transaction costs settled in equity	4,984,000
Company transaction costs paid in cash	3,692,000
Total consideration transferred	112,543,000
Assets
Cash and cash equivalents	44,000
Total assets	44,000
Liabilities assumed:
Accrued expenses and other current liabilities	4,965,000
Total liabilities	4,965,000
Net assets acquired	(4,921,000)
In-process research and development	117,464,000
Net Assets acquired	$ 112,543,000
Price per share (in dollars per share) | $ / shares	$ 1.00
Percentage of discount on share price	10.00%
Number of programs | Program	2
Transaction costs	$ 8,676,000
Acquired in-process research and development		$ 117,464,000
Number of directors appointed | director	3
Trawsfynydd IPR&D | Series C
Consideration transferred:
Consideration transferred	$ 93,232,000
Liabilities assumed:
Number of shares issued | shares	10,359
Shares issuable upon conversion | shares	10,000	400
Trawsfynydd IPR&D | Series C | Tungsten
Liabilities assumed:
Number of shares issued | shares	535
Trawsfynydd IPR&D | Common Stock
Consideration transferred:
Consideration transferred	$ 3,550,000
Liabilities assumed:
Number of shares issued | shares	141,982
Trawsfynydd IPR&D | Common Stock | Tungsten
Liabilities assumed:
Number of shares issued | shares	6,747